PharmaJet®, a leader in needle-free drug delivery systems designed to improve outcomes and patient comfort, has confirmed a new Distribution Agreement with ATR, an affiliate company of EVA Pharma. EVA Pharma is widely recognised for its healthcare innovation and wide-reaching market presence across the Middle East and Africa. The agreement, signed during the CPHI meeting in Frankfurt on 30 October 2025, covers the distribution of Tropis®, advanced technology transfer, and support for eventual local production.

The shared initiative aims to expand the availability of needle-free vaccination options in Egypt and strengthen domestic medical technology capabilities. The Tropis intradermal needle-free delivery platform brings strategic benefits including potential reductions in national polio vaccination costs1, higher vaccine uptake2,3, improved immunisation reach3, and opportunities to produce delivery systems within Egypt. This formal agreement follows the MOU signed in July 2025 by PharmaJet, the Unified Procurement Agency (UPA), and EVA Pharma to explore integrating Tropis into UPA's procurement framework.

The introduction of Tropis supports Egypt's "1000 Golden Days" national programme, which focuses on maternal and early childhood health. By improving vaccination acceptability and lowering overall programme costs, the collaboration is positioned to enhance long-term health and disease prevention. Future manufacturing efforts could also contribute to wider vaccine deployment against additional infectious diseases and reinforce preparedness for public health emergencies.

EVA Pharma's extensive expertise in pharmaceutical manufacturing and regional distribution underpins this collaboration. "This collaboration puts children first," said Riad Armanious, CEO of EVA Pharma. "We're reimagining vaccination through local innovation that improves every child's experience while empowering healthcare professionals. By localizing manufacturing, we expand access and use existing budgets to reach many more children in Africa sustainably."

"We are proud to collaborate with ATR and EVA Pharma to localize needle-free manufacturing and delivery," said Paul LaBarre, Senior Vice President of Business Development for PharmaJet. "This partnership represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region. Working with these innovative teams will accelerate integration of needle-free intradermal vaccine delivery into routine immunization programs in Egypt and beyond."

source:newsreleases.co.uk